Øystein Sandanger

2.2k total citations · 1 hit paper
31 papers, 1.5k citations indexed

About

Øystein Sandanger is a scholar working on Immunology, Molecular Biology and Epidemiology. According to data from OpenAlex, Øystein Sandanger has authored 31 papers receiving a total of 1.5k indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Immunology, 11 papers in Molecular Biology and 6 papers in Epidemiology. Recurrent topics in Øystein Sandanger's work include Inflammasome and immune disorders (10 papers), Immune Response and Inflammation (7 papers) and Chronic Lymphocytic Leukemia Research (5 papers). Øystein Sandanger is often cited by papers focused on Inflammasome and immune disorders (10 papers), Immune Response and Inflammation (7 papers) and Chronic Lymphocytic Leukemia Research (5 papers). Øystein Sandanger collaborates with scholars based in Norway, United States and Germany. Øystein Sandanger's co-authors include Terje Espevik, Arne Yndestad, Pål Aukrust, Trine Ranheim, Harald Husebye, Leif Erik Vinge, Øyvind Halaas, Andreas Brech, Eicke Latz and Bjarne Bogen and has published in prestigious journals such as SHILAP Revista de lepidopterología, The EMBO Journal and The Journal of Immunology.

In The Last Decade

Øystein Sandanger

31 papers receiving 1.5k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

The NLRP3 inflammasome is up-regulated in cardiac fibroblasts and mediates myocardial ischaemia–reperfusion injury

2013 435 citations Øystein Sandanger, Trine Ranheim et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Øystein Sandanger Norway	16	721	621	323	215	184	31	1.5k
Ivan Cuccovillo Italy	19	586 0.8×	496 0.8×	269 0.8×	196 0.9×	151 0.8×	29	1.6k
Charlotte Lawson United Kingdom	17	704 1.0×	468 0.8×	208 0.6×	235 1.1×	139 0.8×	49	1.6k
Hans-Anton Lehr Germany	11	674 0.9×	419 0.7×	186 0.6×	187 0.9×	113 0.6×	13	1.3k
Henry Wu United States	14	744 1.0×	570 0.9×	537 1.7×	431 2.0×	249 1.4×	25	2.2k
Hideharu Abe Japan	21	640 0.9×	443 0.7×	88 0.3×	175 0.8×	120 0.7×	69	1.7k
Ann Jagger United States	12	328 0.5×	825 1.3×	177 0.5×	179 0.8×	207 1.1×	12	1.8k
Fabia Gamboni-Robertson United States	18	751 1.0×	1.0k 1.7×	101 0.3×	210 1.0×	204 1.1×	31	2.2k
Rui Yao China	23	913 1.3×	966 1.6×	485 1.5×	232 1.1×	298 1.6×	55	2.2k
Justin Hartupee United States	15	388 0.5×	780 1.3×	444 1.4×	284 1.3×	127 0.7×	24	1.9k
Wei Luo China	20	683 0.9×	886 1.4×	214 0.7×	150 0.7×	260 1.4×	62	1.8k

Countries citing papers authored by Øystein Sandanger

Since Specialization

Citations

This map shows the geographic impact of Øystein Sandanger's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Øystein Sandanger with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Øystein Sandanger more than expected).

Fields of papers citing papers by Øystein Sandanger

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Øystein Sandanger. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Øystein Sandanger. The network helps show where Øystein Sandanger may publish in the future.

Co-authorship network of co-authors of Øystein Sandanger

This figure shows the co-authorship network connecting the top 25 collaborators of Øystein Sandanger. A scholar is included among the top collaborators of Øystein Sandanger based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Øystein Sandanger. Øystein Sandanger is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Lauritzen, Knut H., Kuan Yang, Michael Frisk, et al.. (2025). Apigenin inhibits NLRP3 inflammasome activation in monocytes and macrophages independently of CD38. Frontiers in Immunology. 15. 1497984–1497984. 2 indexed citations

Kong, Xiang Yi, Knut H. Lauritzen, Tuva B. Dahl, et al.. (2024). CD38 deficient mice are not protected from atherosclerosis. Biochemical and Biophysical Research Communications. 705. 149734–149734. 1 indexed citations

Gehin, Johanna Elin, David J. Warren, Rolf Anton Klaasen, et al.. (2024). Clinical consequences of infliximab immunogenicity and the effect of proactive therapeutic drug monitoring: exploratory analyses of the randomised, controlled NOR-DRUM trials. The Lancet Rheumatology. 6(4). e226–e236. 7 indexed citations

Viken, Marte K., Grethe‐Elisabeth Stenvik, Rolf Anton Klaasen, et al.. (2023). HLA‐DQ2 is associated with anti‐drug antibody formation to infliximab in patients with immune‐mediated inflammatory diseases. Journal of Internal Medicine. 293(5). 648–655. 7 indexed citations

Sandanger, Øystein, et al.. (2023). Nonintensive topical gentamicin treatment of patients with severe epidermolysis bullosa caused by nonsense mutations. SHILAP Revista de lepidopterología. 3(2). 536–546. 2 indexed citations

Gehin, Johanna Elin, Rolf Anton Klaasen, Joe Sexton, et al.. (2023). OP0060 CLINICAL CONSEQUENCES OF INFLIXIMAB IMMUNOGENICITY AND THE IMPACT OF THERAPEUTIC DRUG MONITORING: SECONDARY ANALYSES OF A RANDOMISED CLINICAL TRIAL. Annals of the Rheumatic Diseases. 82. 40–40. 3 indexed citations

Goll, Guro Løvik, Kristin Kaasen Jørgensen, Joseph Sexton, et al.. (2022). Risk factors for anti‐drug antibody formation to infliximab: Secondary analyses of a randomised controlled trial. Journal of Internal Medicine. 292(3). 477–491. 26 indexed citations

Goll, Guro Løvik, Øystein Sandanger, Joe Sexton, et al.. (2022). OP09 Proactive Therapeutic Drug Monitoring is superior to standard treatment during maintenance therapy with infliximab; results from a 52-week multicentre randomised trial of 450 patients; the NOR-DRUM B study. Journal of Crohn s and Colitis. 16(Supplement_1). i010–i010. 1 indexed citations

Syversen, Silje Watterdal, Guro Løvik Goll, Øystein Sandanger, et al.. (2022). 231: PROACTIVE THERAPEUTIC DRUG MONITORING IS SUPERIOR TO STANDARD TREATMENT DURING MAINTENANCE THERAPY WITH INFLIXIMAB; RESULTS FROM A 52-WEEK MULTICENTRE RANDOMISED TRIAL OF 450 PATIENTS. Gastroenterology. 162(7). S–44. 1 indexed citations

10.

Olsen, Maria Belland, Ida Gregersen, Øystein Sandanger, et al.. (2021). Targeting the Inflammasome in Cardiovascular Disease. JACC Basic to Translational Science. 7(1). 84–98. 105 indexed citations

11.

Syversen, Silje Watterdal, Guro Løvik Goll, Kristin Kaasen Jørgensen, et al.. (2020). Therapeutic drug monitoring of infliximab compared to standard clinical treatment with infliximab: study protocol for a randomised, controlled, open, parallel-group, phase IV study (the NOR-DRUM study). Trials. 21(1). 13–13. 27 indexed citations

12.

Yang, Kuan, Trine Ranheim, Knut H. Lauritzen, et al.. (2019). Mammalian Target of Rapamycin (mTOR) and the Proteasome Attenuates IL-1β Expression in Primary Mouse Cardiac Fibroblasts. Frontiers in Immunology. 10. 1285–1285. 13 indexed citations

13.

Gregersen, Ida, Øystein Sandanger, Erik T. Askevold, et al.. (2017). Interleukin 27 is increased in carotid atherosclerosis and promotes NLRP3 inflammasome activation. PLoS ONE. 12(11). e0188387–e0188387. 23 indexed citations

14.

Sokolova, Marina, Leif Erik Vinge, Katrine Alfsnes, et al.. (2016). Palmitate promotes inflammatory responses and cellular senescence in cardiac fibroblasts. Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids. 1862(2). 234–245. 44 indexed citations

15.

Ueland, Thor, Christen P. Dahl, Erik T. Askevold, et al.. (2016). Low Circulating Levels of Mitochondrial and High Levels of Nuclear DNA Predict Mortality in Chronic Heart Failure. Journal of Cardiac Failure. 22(10). 823–828. 21 indexed citations

16.

Sjaastad, Ivar, Helge Scott, Øystein Sandanger, et al.. (2015). Sustained Toll-Like Receptor 9 Activation Promotes Systemic and Cardiac Inflammation, and Aggravates Diastolic Heart Failure in SERCA2a KO Mice. PLoS ONE. 10(10). e0139715–e0139715. 11 indexed citations

17.

Sandanger, Øystein, Erhe Gao, Trine Ranheim, et al.. (2015). NLRP3 inflammasome activation during myocardial ischemia reperfusion is cardioprotective. Biochemical and Biophysical Research Communications. 469(4). 1012–1020. 88 indexed citations

18.

Ohm, Ingrid Kristine, Katrine Alfsnes, Maria Belland Olsen, et al.. (2014). Toll-Like Receptor 9 Mediated Responses in Cardiac Fibroblasts. PLoS ONE. 9(8). e104398–e104398. 15 indexed citations

19.

Grimstad, Øystein, Øystein Sandanger, Liv Ryan, et al.. (2011). Cellular sources and inducers of cytokines present in acute wound fluid. Wound Repair and Regeneration. 19(3). 337–347. 51 indexed citations

20.

Husebye, Harald, Øyvind Halaas, Harald Stenmark, et al.. (2006). Endocytic pathways regulate Toll‐like receptor 4 signaling and link innate and adaptive immunity. The EMBO Journal. 25(4). 683–692. 379 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact